Apr 19, 2013 - 3:32 pm
My mom was recently diagnosed with Kidney cancer. They removed her kidney about two weeks ago. The tumors have also spread to her lungs. She is 72 years old and in pretty good health otherwise.
She is now weighing the choice between starting Sutent or entering a trial that combines Nivolumab and Ipilimumab.
Is there an obvious choice with one route clearly being better than the other?